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T h e n o n e n z y m a t i c r e a c t i o n o f r e d u c i n g s u g a r s w i t h proteins and lipids leads to the formation of Schiff bases and Amadori products. These early glycated products may undergo complex rearrangements resulting in the formation of advanced glycation end-products (AGEs), a process known as the Maillard reaction (1). Conventional peritoneal dialysis (PD) fluids contain glucose at supraphysiological concentrations (75 -214 mmol/L). Under these conditions, proteins in the peritoneal cavity may be glycated, with subsequent formation of AGEs. Indeed, in vitro incubations of albumin with dialysates resulted in a glucose-and timedependent increase of glycated albumin and AGEs (2); glycation of albumin and AGE formation occurs in the peritoneal cavity of PD patients (3, 4) . Immunohistochemical staining shows that AGEs accumulate in the mesothelial layer, the connective tissue, and the vascular wall of the peritoneum of patients on continuous ambulatory peritoneal dialysis (CAPD) treatment (4) (5) (6) . The formation of AGEs in the peritoneum of patients on PD treatment is proposed to be involved in pathophysiological alterations of the peritoneal membrane (2), which may be followed by a severe impairment of the peritoneum 4 
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and a loss of ultrafiltration capacity in PD (7) . In addition, Amadori albumin has also been shown to induce receptor-mediated responses (8) (9) (10) ) that may be involved in complications during PD. There is, however, a lack of information on the presence of early-glycated proteins in the peritoneum. One aim of this study was, therefore, to study the presence of Amadori albumin in dialyzed peritoneal membrane. Because of the detrimental effects of glucose, the glucose polymer icodextrin may be a better osmotic agent in PD. Icodextrin is capable of inducing sustained ultrafiltration and is, therefore, effective during long dwells such as the daytime dwell in continuous cycling peritoneal dialysis (CCPD) (11) . In vitro studies showed that icodextrin PD solution resulted in less glycation and formation of protein-linked AGEs than conventional PD solutions (12) . Because we were interested in the biocompatibility of icodextrin, the formation of Amadori albumin and AGEs in icodextrin was studied both in vitro and ex vivo in effluents of CCPD patients using glucose or icodextrin for their daytime dwell. Mass transfer area coefficient (MTAC) studies were done to investigate transport kinetics of Amadori albumin in the dialysates.
PATIENTS PATIENTS PATIENTS PATIENTS PATIENTS
Twenty-four stable adult CCPD patients (23 nondiabetics), aged 26 -73 years, 17 males and 7 females, were included in the effluent study. All patients were treated with glucose-containing dialysis solutions (Dianeal, 1.36%, 2.27%, or 3.86% w/v glucose; Baxter BV, Utrecht, The Netherlands) for their overnight exchanges. Twelve patients (mean ± SEM: age 51.1 ± 5 years, duration on PD 34.2 ± 7 months) were randomized to use Dianeal, and 12 patients (age 54.8 ± 3.1 years, duration on PD 40.3 ± 5.9 months) to use icodextrin for their daytime dwell. The mean ± SEM duration of icodextrin use was 18.5 ± 1.7 months.
A standard peritoneal permeability analysis (SPA), as previously described by Pannekeet et al. (13) , was performed to calculate MTACs of 16 CCPD patients. Eight patients used Dianeal (mean ± SEM: duration on PD 37.4 ± 9.5 months) and 8 used icodextrin (duration on PD 32.9 ± 6.9 months, duration of icodextrin use 15.3 ± 2.1 months) for their daytime dwell. All MTACs were done with a Dianeal 1.36% test bag. Patients had not experienced a peritonitis episode for at least 4 weeks before the dialysate collection. The Free University Hospital Ethical Committee approved the study and written informed consent was obtained from each patient.
MATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODS

REAGENTS AND MEASUREMENTS
Human serum albumin (HSA) and aminoguanidine hydrochloride were obtained from Sigma Chemicals (St. Louis, MO, U.S.A.). Baxter BV (Utrecht, The Netherlands) provided PD solutions (Dianeal 1.36%, 2.27%, and 3.86% w/v glucose). Icodextrin [molecular weight (MW) 16 200, 7.5% solution] was manufactured and supplied by ML Laboratories plc (Blaby, United Kingdom). The filter-sterilized PD fluids (with composition identical to the commercial PD solutions) were prepared in the laboratory (Baxter, Chicago, IL, U.S.A. and ML Laboratories plc) and filter sterilized (0.2 µ filter).
Albumin was measured by an immunochemical method (rate nephelometry) from Beckman Instruments (Galway, Ireland). An automated analyzer (Hitachi 747, Boehringer, Mannheim, Germany) measured creatinine, urea, urate, and total protein content using colorimetric methods.
MEASUREMENT OF AGE ALBUMIN/PROTEIN-DERIVED FLUORESCENCE
Fluorescence measurements were done with a Perkin-Elmer LS-30 luminescence spectrophotometer (Perkin-Elmer, Zoetermeer, The Netherlands). AGE fluorescence was determined at the excitation and emission maxima (excitation 350 nm, emission 430 nm, slit 4 Preparation of a polyclonal anti-Amadori HSA antibody and the specificity of the antiserum have been described in detail elsewhere (14) . Briefly, glycated HSA [prepared by incubating HSA (50 mg/mL) for 8 weeks at 37°C in sterile 0.1 mol/L sodium phosphate buffer (pH 7.4) with 0.5 mol/L D-glucose] was emulsified in a same volume of specol (Central Veterinary Institute, Lelystad, The Netherlands). Two rabbits were intradermally injected in multiple sites. The rabbits were boosted with the same amount of AGE HSA 30 days later, and antisera were obtained 10 days after the booster. This procedure was repeated three times. Ten days after the fourth and final booster, the rabbits were bled and their sera used. The antisera were dialyzed against 0.05 mol/L Tris-buffer (pH 8.3) and passed over DEAE-Sephacel (Pharmacia, Uppsala, Sweden). In order to remove antibodies reactive to HSA, the nonadsorbed fraction was then applied to a column of HSA coupled to CnBr-activated Sepharose 4B (Pharmacia). The coupling of HSA to CnBr-activated Sepharose was performed following the manufacturer's instruction. The nonadsorbed fraction was applied to a column of AGE HSA coupled to CnBractivated Sepharose 4B. After washing, immunoaffinity-purified antibodies against AGE HSA were eluted with 0.1 mol/L glycine buffer (pH 2.5) including 0.5 mol/L NaCl. The antibody fractions were pooled and dialyzed against 0.05 mol/L Tris-buffer (pH 7.4) including 0.15 mol/L NaCl and 0.01% sodium azide.
The antibodies reacted with glucose-modified HSA preparations, but not with native HSA, or with glucose-6-phosphate-modified HSA, glucose-modified BSA, or glucosemodified ovalbumin. Even at physiological glucose concentrations of 5 mmol/L, a slow but significant time-dependent product was formed that showed binding to the antibody. Albumin modifications with D-ribose or pyruvate, or with the dicarbonyls, 3-deoxyglucosone, methylglyoxal, or glyoxal, yielded a time-dependent increase of AGE fluorescence in all cases, while none of the adducts showed any cross-reactivity with the antibodies. The well-characterized AGEs, CML HSA or pentosidine, failed to inhibit the antibody binding to glycated HSA. Aminoguanidine (200 mmol/L) completely reduced the formation of AGE-associated fluorescence, while this preparation contained only 20% less recognition to the antibody. Glycated HSA treated with NaBH 4 , which is effective in the reduction of Amadori products but not of AGEs, showed a lower detection than nonreduced glycated HSA, suggesting that the epitope recognized is an early-stage Amadori glycation product. Further evidence that the antibodies recognized Amadori products was provided by the fact that the well-defined synthetic fructosamine standard, 3-deoxy-1-morpholino-D-fructose, inhibited the antiserum binding to glycated HSA in the competitive ELISA. Based on the characterization of the recognition epitope as an Amadori glycation product, we denote the antibody as an anti-Amadori albumin antibody.
ELISA PROCEDURE
In a noncompetitive ELISA performed at room temperature, each well was coated with 100 µL of 0.1 mg/mL AGE effluents in phosphate-buffered saline (PBS) for 1 hour. The wells were washed twice with PBS and each well was then blocked with 150 µL 0.5% gelatin in PBS for 1 hour. Wells were subsequently washed three times with PBS containing 0.05% Tween 20 (PBS-Tween) and incubated for 1 hour with immunoaffinitypurified anti-Amadori HSA antibody in PBS-Tween (1:100) including 1 mg/mL HSA. After 3 washes with PBS-Tween, the wells were incubated with 100 µL peroxidase-labeled goat antirabbit (1:2000, Dako, Slostrup, Denmark) for 1 hour. Finally, the wells were washed 5 times with PBS-Tween and the substrate was developed with 100 µL tetramethylbenzidine. The reaction was stopped with 100 µL 1 N H 2 SO 4 . The extinction at 450 nm was measured with a multichannel spectrophotometer (SLT Microplate Reader, Wilten Bioteknika, Etten-Leur, The Netherlands). Human serum albumin (10 g/L) was incubated at pH 7.2 with icodextrin and Dianeal (1.36%, 2.27%, and 3.86%). These incubations were done with or without 200 mmol/L aminoguanidine. Aliquots were removed at 0, 1, 3, 7, and 14 days, and stored at -70°C until analysis. Bacterial growth was inhibited by the addition of 0.1% NaN 3 . At analysis, the samples were thawed and mixed well, and AGE fluorescence and Amadori albumin were determined. All results were corrected for background activity.
DIALYSATES
Effluents from a daytime dwell (13 -16 hours) were collected in the evening and immediately stored in the patient's refrigerator until further processing the next day. Cells were separated from the effluents by centrifugation at 1000g for 10 minutes at 4°C in 500 mL plastic buckets. The cell-free supernatants were stored at -70°C until analysis. The MTAC samples were stored at -70°C until analysis.
IN VIVO CONCENTRATION OF AGEs
Peritoneal effluents from patients on CCPD were collected as described above. At the time of analysis, the stored supernatant PD effluents were thawed and mixed well, and their AGE fluorescence and Amadori albumin determined. Albumin and total protein content were determined in all effluents. Albumin was measured in dialysate and plasma samples at 240 minutes.
IMMUNOHISTOCHEMISTRY
A biopsy of the dialyzed peritoneum was derived from a male CCPD patient aged 25 years with a PD duration of 39 months. The control sample was taken from the peritoneum of a patient who underwent surgery for a colon carcinoma. Both biopsies were fixed in formaldehyde and embedded in low melting point paraffin wax. Transverse sections of formalin-embedded tissue samples were cut at 5 µ. For immunohistochemistry, endogenous peroxidase activity was blocked by 0.3% H 2 O 2 (v/v) in methanol. All reagents were diluted in PBS containing 1% bovine serum albumin (BSA) (w/v). After Subsequently, the effect of aminoguanidine on the formation of Amadori albumin and AGEs by PD fluids was studied. Aminoguanidine completely inhibited the development of AGE formation in both icodextrin-and glucose-based PD solutions, but the formation of Amadori albumin was only partially (up to 20%) inhibited by aminoguanidine (Figure 2 ). To study whether the process of heat sterilization influenced the development of Amadori albumin and AGEs, we compared the formation of glycated products in heatsterilized glucose-based PD fluids with filter-sterilized fluids. The formation of 
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No differences were found in Amadori albumin and AGE levels in effluents collected from stable CCPD patients using either Dianeal (n = 12) or icodextrin (n = 12) for their daytime dwells (Table 1) , as determined with and without correction for total protein or albumin content in the effluents.
The MTAC studies revealed a significant increase in dialysate Amadori albumin concentration over time (p < 0.0001), with no difference between glucose and icodextrin users ( Table 2 ). The dialysate Amadori albumin concentration at 240 minutes dwell time was significantly correlated with duration on PD (Figure 3) . In contrast, serum Amadori albumin concentration was not related to PD duration. The Amadori albumin D/P ratio (0.82 ± 0.11) did not differ between the groups; the albumin D/P ratio was 0.010 ± 0.003. The calculated albumin clearance (D × V/P) in the whole group was 0.089 ± 0.017 mL/minute and the calculated Amadori albumin clearance was 7.71 ± 1.14 mL/ minute (p < 0.0001).
IMMUNOHISTOCHEMICAL DETECTION OF AMADORI ALBUMIN
In the peritoneal biopsy of the CCPD patient, fibrosis was found in the submesothelial layer of the peritoneum [Figures 4(a), 4(b), and 4(d) ]. In this patient, Amadori albumin was found on the mesothelium and on the superficial submesothelial layer of the (2) (3) (4) . In this study, we confirmed a rapid formation of AGEs, evident already within 1 day, in PD fluids upon incubation with HSA. Using a specific antibody against Amadori albumin, we also demonstrated the formation of the early-glycated product Amadori albumin. However, the rate at which Amadori albumin appeared was much slower than the rapid initial increase observed in AGE formation. Human serum albumin incubated in icodextrin resulted in a much lower formation of AGEs than in commercially available Dianeal solutions; the formation of Amadori albumin was also very low in icodextrin.
In general, the formation of AGEs in PD fluids may be categorized into two mechanisms: (1) a glucose-dependent formation of early Amadori products that, over a long period of time, will undergo chemical reactions and rearrangements and will ultimately result in the formation of AGEs; (2) a rapid formation of AGEs through the interaction of proteins with glucose auto-oxidation products such as arabinose, methylglyoxal, and glyoxal, and fragmentation products of Amadori products such as 3-deoxyglucosone (15, 16) , which are present in PD fluids in high concentrations (17) (18) (19) .
The most likely explanation for the rapid initial increase in AGE fluorescence is the presence of AGE intermediates in heat-sterilized PD fluids and the very rapid interaction of these intermediates with proteins, resulting in AGE formation. The AGE formation was completely suppressed by aminoguanidine. Since aminoguanidine has been shown to inhibit AGE formation by reacting with carbonyl intermediates, while the amount of Amadori products remained essentially unchanged (20) , these results also demonstrate that carbonyl intermediates, rather than glucose itself, are the direct precursors of the formation of AGEs. In contrast, but in complete agreement with the specificity of aminoguanidine, the formation of Amadori albumin in PD fluids was only partially inhibited by aminoguanidine. Finally, heat-sterilization, which is known to induce the formation of reactive carbonyl intermediates (18, 19) , strongly accelerated the formation of AGEs but not of Amadori albumin, also confirming that AGE intermediates, rather than glucose itself, are involved in AGE formation in PD fluids. In contrast to the rapid formation of AGEs by their reactive intermediates, the formation of Amadori albumin is much slower, probably as a consequence of the slow kinetics of the glucosepathway (see above).
Using a polyclonal antibody against Amadori albumin, we were able, for the first time, to demonstrate with immunohistochemical analysis the presence of Amadori albumin in the mesothelial layer and the vascular wall of the peritoneum of CCPD patients. Therefore, interaction of Amadori albumin, with specific receptors on endothelial and mesothelial cells, may induce receptor-mediated responses. Glycated albumin has been shown to stimulate nitric oxide (NO) and tumor necrosis factor α gene expression and to modulate NO synthase activity on endothelial cells (8) , and transforming growth factor β and type IV collagen gene expression on glomerular mesangial fibronectin (9, 10) . Therefore, Amadori albumin accumulation in the peritoneum may be involved in pathophysiological alterations and morphological damage of the peritoneal membrane leading to complications in PD patients.
The formation of AGEs in icodextrin was significantly lower compared to the formation of AGEs in the weakest commercially available glucose-based PD fluid. Consistent with a role of 1,2-dicarbonyl compounds in the formation of AGEs, the concentrations of these intermediates in icodextrin are indeed significantly lower compared to glucosebased PD fluids (21) . Low levels of Amadori albumin were formed in icodextrin, as 5 Icodextrin is a glucose polymer of glucose, with 90% in a MW range of 1638 -45 000 Da. Glycation involves the condensation reaction of the carbonyl group of sugar aldehydes with free amino groups of proteins. Using an average MW for icodextrin of 16 200 Da, 7.5% icodextrin represents 4.5 mmol/L free carbonyl groups. This is at least 17-fold lower than in a PD fluid of 75 mmol/L glucose (1.36%). In agreement, the formation of Amadori albumin, as demonstrated with our specific antibody, was much lower in icodextrin than in 1.36% glucose (16 ± 2 vs 1 ± 1 U/mg respectively). Also in agreement with our results, Dawnay and Millar (12) also demonstrated that the formation of glycated albumin in icodextrin, as detected with boronate affinity chromatography, was more than tenfold lower compared to 1.36% glucose. We were not able to show a difference in PD effluent Amadori albumin or AGE concentrations between icodextrin and Dianeal users. The patients on icodextrin only used icodextrin for the long daytime dwell and used glucose in all other CCPD exchanges, which probably explains why no difference between the groups was found. The MTAC studies showed a positive relationship between dialysate Amadori albumin concentrations and duration of PD treatment.
BANTAO
Recently, there was described in CAPD patients a peritoneal albumin-linked pentosidine clearance higher than albumin clearance, although the albumin-linked molecule is larger (22) . The authors suggested an active peritoneal transport mechanism or a facilitated diffusion of protein-linked pentosidine to the peritoneal cavity. In addition, it was described that the glycated/nonglycated clearance ratios for albumin and other peritoneal proteins was slightly, but significantly, increased (23, 24) . We also calculated a higher Amadori-albumin/albumin clearance ratio, which was, however, much higher than previously reported. It might be that differences in the detection of different early glycated products and, in addition, differences in dwell time between CCPD and CAPD may explain these findings. However, based on the MWs of albumin and Amadori albumin, it is very unlikely that the clearance rate of Amadori albumin is 90-fold higher than that of albumin. Furthermore, the lack of a relationship between the serum concentration of Amadori albumin and PD duration, while the dialysate concentration of Amadori albumin was positively related to PD duration, also gave reason to doubt such a preferential clearance of Amadori albumin. These observations made it very unlikely that Amadori albumin "clearance" is much higher than albumin clearance. The high Amadori albumin concentrations in the effluents are more likely due to a washout of Amadori albumin from the peritoneal membrane, and may be due to local Amadori albumin formation in or adjacent to the peritoneal cavity. The immunohistochemical detection of Amadori albumin in the peritoneal membrane of our CCPD patient favors the possibility of a washout of Amadori albumin from the peritoneal membrane.
In conclusion, the formation of AGEs in icodextrin is lower than in all commercially available glucose solutions tested. Aminoguanidine inhibits AGE formation. However, no Amadori albumin is formed in icodextrin, which contrasts strongly to the extensive formation of these products in glucose-based PD fluid. The concentrations of Amadori albumin were the same in effluents of CCPD patients using glucose or icodextrin during daytime dwells. Peritoneal transport studies showed a positive relationship between dialysate Amadori albumin concentrations and duration on PD, and an Amadori albumin clearance that was much higher than the albumin clearance. The latter observation suggests washout of locally formed Amadori albumin in or adjacent to the peritoneal cavity. Thus, icodextrin-based PD fluids largely prevent at least one mechanism that leads to the accumulation of potentially damaging AGEs.
